ACAD Stock Performance, Insider Transaction and News

ACAD - ACADIA Pharmaceuticals Inc.

Market Cap	4.75B	P/E	-	EPS this Y	254.10%	Ern Qtrly Grth	-
Income	-1.71M	Forward P/E	45.63	EPS next Y	94.70%	50D Avg Chg	12.00%
Sales	813.81M	PEG	-0.07	EPS past 5Y	-	200D Avg Chg	45.00%
Dividend	N/A	Price/Book	12.06	EPS next 5Y	-357.00%	52W High Chg	-14.00%
Recommedations	2.10	Quick Ratio	1.73	Shares Outstanding	165.22M	52W Low Chg	113.00%
Insider Own	0.49%	ROA	-0.38%	Shares Float	107.79M	Beta	0.42
Inst Own	100.95%	ROE	-0.41%	Shares Shorted/Prior	12.03M/11.20M	Price	29.20
Gross Margin	50.23%	Profit Margin	-0.21%	Avg. Volume	1,634,129	Target Price	27.28
Oper. Margin	7.39%	Earnings Date	Jul 31	Volume	1,707,063	Change	0.90%

Healthcare | Biotechnology | United States

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc. News

05/17/24	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/15/24	Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
05/11/24	Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
05/10/24	ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
05/10/24	ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/09/24	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
05/09/24	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
05/09/24	ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...
05/08/24	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
05/08/24	Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
05/06/24	Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
05/04/24	Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)
04/29/24	Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
04/28/24	ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
04/24/24	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
04/22/24	Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
04/17/24	Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
04/11/24	3 Pharma Stocks to Sell in April Before They Crash & Burn
04/10/24	ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
04/02/24	Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

ACAD Chatroom

Downsiderisk Posted - 1 day ago

$ACAD old Zeusy boy searching for any news to move this stock. Now he's hoping Stevie creates fake news of a buyout!! One word Zeus... PATHETIC!!!!!

GI197845 Posted - 1 day ago

$ACAD Uh Oh!~ More and more inducements!

jacksonjohn750 Posted - 1 day ago

$ACAD must die first

sdx8 Posted - 1 day ago

$ACAD added

VolumePrice Posted - 2 days ago

$ACAD adding patiently, eventually MMs will let it go up huge

HorizonBull Posted - 2 days ago

$ACAD added 14.66

zeustony88 Posted - 2 days ago

$ACAD Many, many years ago, we would have these buyout rumors pop out of nowhere. Maybe Stevie boy pulls one out of his hat to get some heat off his back? At this point, any news is good news.

GI197845 Posted - 2 days ago

$ACAD It's too bad that the recent proxy vote, did not have a question about...Should Steve Davis remain as CEO yes or no. I would have voted No. How do we get rid of this F'er and get a better CEO?

GI197845 Posted - 2 days ago

$ACAD Here is an interesting article that states that weight loss drugs could bankrupt medicare: https://www.beckershospitalreview.com/glp-1s/sanders-weight-loss-drug-could-bankrupt-healthcare-system.html?utm_medium=email&utm_content=newsletter The reason this is noteworthy, is that a large percentage of the cost of Nuplazid and Trofinetide are covered by medicare and insurance and if you take those away, Acadia's sales would be down by probably 80%. Also, another interesting thing is that it shows how much weight loss drugs are sold for in the USA vs Canada and other countries, meaning that when Daybue/Trofinetide is sold in Canada, it won't increase Acadia's sales much and may hurt Acadia if USA patients can get Daybue for 99% cheaper in Canada and have it shipped to the USA, or just jump across the border, buy and jump back across the border to the USA. Novo Nordisk charges $969 per month for Ozempic in the U.S., compared to $155 in Canada, $122 in Italy, $71 in France and $59 in Germany. The drug manufacturer lists Wegovy for $1,349 per month in the U.S.

GI197845 Posted - 2 days ago

$ACAD I don't think Acadia will be sold or bought out, because they don't have enough to offer and they don't have a good enough pipeline, just my opinion. The Baker Brothers did not push for the failed Kodiak Sciences-KOD to be bought out, so why would they push for ACAD to be bought out. Maybe in a few years if Acadia can get an Alzheimer's Disease Psychosis drug approved, buy that time, Alzheimer's will have been cured by stem cell therapies.

Downsiderisk Posted - 2 days ago

$ACAD here comes $10!!!!

Downsiderisk Posted - 2 days ago

$ACAD still making money with this disaster!!! Thanks Steve!

sdx8 Posted - 2 days ago

$ACAD Why hasn’t baker brothers pushed for buyout?

Downsiderisk Posted - 2 days ago

$ACAD

GI197845 Posted - 2 days ago

$ACAD Hey Hey Ho Ho, Steve Davis has got to go!

zeustony88 Posted - 2 days ago

$ACAD Well if Bakers not selling their shares.......

sdx8 Posted - 2 days ago

$ACAD surprised not acquired by now. Maybe time to buy?

HorizonBull Posted - 3 days ago

$ACAD added

jacksonjohn750 Posted - 3 days ago

$ACAD let’s dip n rip

SBL71 Posted - 3 days ago

$ACAD proxy vote cast this AM. Need an ‘open comment’ section.

Pika_Capital Posted - 3 days ago

$acad starter at these levels

howardlindzon Posted - 3 days ago

$ACAD $AGYS $ALC $NNI fresh trends with no friends

Downsiderisk Posted - 3 days ago

$ACAD this ship is going down with Captain Stevie

RonIsWrong Posted - 3 days ago

$ACAD https://www.fiercepharma.com/marketing/acadia-adds-awareness-raising-adventure-series-site-dedicated-documenting-life-rett Acadia adds awareness-raising adventure series to site dedicated to documenting life with Rett syndrome

jacksonjohn750 Posted - 4 days ago

$ACAD 15 calls are killing it... let's do dis

RichieMagaoneCarter Posted - 4 days ago

$ACAD bought again

tradingtwenty Posted - 4 days ago

Top 5 oversold stocks that have trended in the past 24 hours: $CRNC 17.75 🔥 $SPT 19.88 $FWRD 22.64 $TMCI 23.11 $ACAD 25.17 Values range from 0 to 100, where 30 or below is oversold and 70 or above overbought. Link: https://tradingtwenty.com/dashboard/trending/past

Stock_Titan Posted - 4 days ago

$ACAD Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-announces-launch-of-magnolia-s-guide-to-hgg0z18sb9vc.html

HorizonBull Posted - 4 days ago

$ACAD no brainer. 1B revenue in next Quarter. buy and hold

jacksonjohn750 Posted - 4 days ago

$ACAD Let's go!!!

Analyst Ratings

B of A Securities	Neutral	May 10, 24
HC Wainwright & Co.	Buy	May 9, 24
Citigroup	Buy	May 9, 24
Stifel	Hold	May 9, 24
Cantor Fitzgerald	Overweight	May 9, 24
Mizuho	Neutral	May 9, 24
Needham	Buy	May 9, 24
Baird	Outperform	May 9, 24
Oppenheimer	Perform	May 6, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
DAVIS STEPHEN	CEO CEO	Jan 06	Sell	29.96	3,732	111,811	96,521	01/09/24
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Jan 06	Sell	29.96	731	21,901	30,949	01/09/24
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Jan 06	Sell	29.96	590	17,676	46,901	01/09/24
Kihara James	Principal Accounting.. Principal Accounting Officer	Dec 15	Sell	28.30	2,000	56,600	11,025	12/15/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Nov 17	Sell	22.64	4,960	112,294	30,393	11/21/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Nov 17	Sell	22.64	5,108	115,645	20,486	11/21/23
Kihara James	Principal Accounting.. Principal Accounting Officer	Nov 17	Sell	22.64	1,985	44,940	13,025	11/21/23
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Oct 05	Sell	21.96	16,369	359,463	45,857	10/06/23
DAVIS STEPHEN	CEO CEO	Oct 05	Sell	21.96	51,563	1,132,323	89,131	10/06/23
Kihara James	Principal Accounting.. Principal Accounting Officer	Sep 15	Sell	25.88	2,000	51,760	10,778	09/19/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Aug 21	Sell	28.997	10,000	289,970	15,682	08/23/23
DAVIS STEPHEN	CEO CEO	Jul 14	Option	20.77	100,000	2,077,000	136,695	07/18/23
DAVIS STEPHEN	CEO CEO	Jul 14	Sell	30.04	100,000	3,004,000	36,695	07/18/23
DAVIS STEPHEN	CEO CEO	Jul 11	Sell	25.03	71,602	1,792,198	36,695	07/13/23
Brege Laura	Director Director	Jun 12	Sell	24.868	4,500	111,906	13,502	06/14/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Jun 08	Sell	25.02	974	24,369	22,824	06/12/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Jun 08	Option	0	1,893		23,798	06/12/23
BAKER BROS. ADVISORS LP	Director Director	May 22	Buy	25.22	896,522	22,610,285	39,317,673	05/24/23
BAKER BROS. ADVISORS LP	Director Director	May 22	Option	17.01	25,000	425,250	38,620,261	05/24/23
Kihara James	Principal Accounting.. Principal Accounting Officer	May 17	Sell	22.5	5,947	133,808	11,144	05/19/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	May 17	Sell	22.5	15,310	344,475	21,905	05/19/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	May 17	Sell	22.5	14,869	334,552	24,356	05/19/23
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Apr 29	Sell	21.18	917	19,422	25,513	05/02/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Apr 29	Sell	21.18	548	11,607	9,487	05/02/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Apr 29	Option	0	1,567		10,035	05/02/23
DAVIS STEPHEN	CEO CEO	Apr 29	Sell	21.18	7,806	165,331	108,297	05/02/23
DAVIS STEPHEN	CEO CEO	Apr 29	Option	0	15,625		116,103	05/02/23
Kihara James	Principal Accounting.. Principal Accounting Officer	Apr 07	Sell	18.14	523	9,487	5,197	04/11/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Apr 05	Sell	18.16	1,751	31,798	8,468	04/07/23
Kihara James	Principal Accounting.. Principal Accounting Officer	Apr 05	Sell	18.16	701	12,730	4,231	04/07/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Apr 05	Sell	18.16	1,916	34,795	7,477	04/07/23
DAVIS STEPHEN	CEO CEO	Apr 05	Sell	18.16	8,582	155,849	100,478	04/07/23
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Apr 05	Sell	18.16	1,456	26,441	23,425	04/07/23
Kihara James	Principal Accounting.. Principal Accounting Officer	Feb 23	Sell	18.78	350	6,573	2,923	02/27/23
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Feb 23	Sell	18.78	577	10,836	4,118	02/27/23
DAVIS STEPHEN	CEO CEO	Feb 23	Sell	18.78	3,851	72,322	91,727	02/27/23
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Feb 23	Sell	18.78	803	15,080	20,108	02/27/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Feb 23	Sell	18.78	461	8,658	5,195	02/27/23
BAKER BROS. ADVISORS LP	Director Director	Jan 12	Option	5.22	30,000	156,600	38,484,981	01/17/23
DAVIS STEPHEN	CEO CEO	Jan 06	Sell	17.13	3,904	66,876	84,633	01/10/23
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Jan 06	Sell	17.13	532	9,113	4,549	01/10/23
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Jan 06	Sell	17.13	589	10,090	18,697	01/10/23
Stankovic Srdjan R.	President President	Oct 15	Sell	15.81	1,326	20,964	56,831	10/18/22
DAVIS STEPHEN	CEO CEO	Oct 15	Sell	15.81	2,804	44,331	79,009	10/18/22
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Jun 08	Option	0	1,893		3,995	06/10/22
Schneyer Mark C.	EVP, Chief Financial.. EVP, Chief Financial Officer	Jun 08	Sell	17.91	653	11,695	3,342	06/10/22
DAVIS STEPHEN	CEO CEO	Apr 29	Sell	18.18	5,483	99,681	75,875	05/03/22
Stankovic Srdjan R.	President President	Apr 29	Sell	18.18	2,865	52,086	55,188	05/03/22
KIM AUSTIN D.	EVP,General Counsel,.. EVP,General Counsel, Secretary	Apr 29	Sell	18.18	894	16,253	16,742	05/03/22
Teehan Brendan	EVP, COO, Head of Co.. EVP, COO, Head of Commercial	Apr 29	Sell	18.18	552	10,035	3,437	05/03/22